Oppenheimer Thinks BioNano Genomics’ Stock is Going to Recover

By Austin Angelo

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on BioNano Genomics (BNGOResearch Report), with a price target of $1.50. The company’s shares closed last Thursday at $0.51, close to its 52-week low of $0.25.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 25.3% and a 51.1% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Orchard Therapeutics.

Currently, the analyst consensus on BioNano Genomics is a Strong Buy with an average price target of $1.83.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.70 and a one-year low of $0.25. Currently, BioNano Genomics has an average volume of 7.39M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.